Bushen Jianpi Formula Combined with Entecavir for the Treatment of HBeAg-Negative Chronic Hepatitis B: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
Table 3
Adverse events reported during the follow-up period.
Adverse event
Treatment group (n = 271)
Control group (n = 272)
Abnormal CBC
51 (18.8)
37 (13.6)
0.111
Abnormal kidney function
0 (0.0)
6 (2.2)
0.028
Abnormal stool analysis
7 (2.6)
2 (0.7)
0.156
Abnormal urine test
47 (17.3)
31 (11.4)
0.069
Abnormal ECG
3 (1.1)
4 (1.5)
0.643
Diarrhea
19 (7.0)
23 (8.5)
0.630
Gingival bleeding
22 (8.1)
32 (11.8)
0.197
Fatigue
28 (10.3)
26 (9.6)
0.776
Fever
6 (2.2)
8 (3.7)
0.448
Abdominal pain
42 (15.5)
59 (21.7)
0.077
Any other complaints
3 (1.2)
8 (3.0)
0.216
CBC, complete blood count; ECG, electrocardiogram. Other complaints included injury, extrauterine pregnancy, and intracranial tumor.
